The New England Journal of Medicine
Pelacarsen did not lower major cardiovascular event risk
Major cardiovascular events occurred in 12.3% of pelacarsen recipients and 12.1% of placebo recipients over a median 4.7 years.Major cardiovascular events occurred in 12.3% of pelacarsen recipients and 12.1% of placebo recipients over a median 4.7 years.
Randomized trial · 8,322 peoplePelacarsen
Who was studied8,322 patients with cardiovascular disease and high lipoprotein(a)
What changedMajor cardiovascular events did not differ: 12.3% with pelacarsen against 12.1% with placebo
The catchThe efficacy analysis included only 8,322 of the 8,350 randomized patients
